HEXIM1, HEXIM P-TEFb complex subunit 1, 10614

N. diseases: 46; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental
0.300 Biomarker disease CTD_human Systems level analysis and identification of pathways and networks associated with liver fibrosis. 25380136 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE RNAi knockdown of KDM5B induced HEXIM1 expression, thus validating the specific negative regulation of tumor suppressor HEXIM1 by the H3K4me3/2 demethylase KDM5B. 31805991 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE We previously reported that the tumor suppressor HEXIM1 is a mediator of KDM5B recruitment to its target genes, and HEXIM1 is required for the inhibition of nuclear hormone receptor activity by KDM5B. 31776402 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE HEXIM1 is described as an excellent pharmacodynamic biomarker for target engagement in tumors as well as in blood. 29491412 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE Our findings suggest the potential of ubenimex adjuvant treatment to enhance JQ1 efficiency and attenuate parts of its side effect (enhancing tumor aggressive) by regulating the autophagic degradation of HEXIM1 and Akt inhibition. 28484091 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues. 27903752 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 AlteredExpression group BEFREE In melanoma, we identify HEXIM1, a transcription elongation regulator, as a melanoma tumor suppressor that responds to nucleotide stress.HEXIM1 expression is low in melanoma. 27058786 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE Nucleotide stress induces the tumor suppressor HEXIM1 to suppress melanoma. 27102073 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 AlteredExpression group BEFREE We have been studying the role of Hexamethylene bisacetamide (HMBA) Induced Protein 1 (HEXIM1) as a tumor suppressor whose expression is decreased in tamoxifen resistant and metastatic breast cancer. 27238569 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. 22098666 2012
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 AlteredExpression group BEFREE Known inhibitors of KDM5B were also able to induce HEXIM1 expression, inhibit cell proliferation, induce differentiation, potentiate sensitivity to cancer chemotherapy, and inhibit breast tumor metastasis. 31805991 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 AlteredExpression group BEFREE Known inhibitors of KDM5B were also able to induce HEXIM1 expression, inhibit cell proliferation, induce differentiation, potentiate sensitivity to cancer chemotherapy, and inhibit breast tumor metastasis. 31805991 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 AlteredExpression group BEFREE Utility of HEXIM1 mRNA may be limited to higher concentrations.<i>Clin Cancer Res; 23(4); 1025-35.©2017 AACR</i>. 28073847 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 Biomarker group BEFREE Incorporating well-characterized pharmacodynamic markers, such as HEXIM1 and other genes described here, can provide a better understanding of potential efficacy and toxicity associated with inhibiting BET family proteins and informs early clinical decisions on BET inhibitor development programs.Mol Cancer Ther; 16(2); 388-96.©2016 AACR. 27903752 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 AlteredExpression group BEFREE Decreased Hexim-1 expression in animal models of chronic diseases such as left ventricular hypertrophy, obesity and cancer triggered significant changes in adaptation and remodeling. 28013147 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 Biomarker group BEFREE Incorporating well-characterized pharmacodynamic markers, such as HEXIM1 and other genes described here, can provide a better understanding of potential efficacy and toxicity associated with inhibiting BET family proteins and informs early clinical decisions on BET inhibitor development programs.Mol Cancer Ther; 16(2); 388-96.©2016 AACR. 27903752 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 AlteredExpression group BEFREE Decreased Hexim-1 expression in animal models of chronic diseases such as left ventricular hypertrophy, obesity and cancer triggered significant changes in adaptation and remodeling. 28013147 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 AlteredExpression group BEFREE Utility of HEXIM1 mRNA may be limited to higher concentrations.<i>Clin Cancer Res; 23(4); 1025-35.©2017 AACR</i>. 28073847 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 Biomarker group BEFREE HEXIM1 plays an important role in inhibiting cancer cell-specific gene transcription while also facilitating anti-cancer gene expression. 27058786 2016
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 Biomarker group BEFREE HEXIM1 plays an important role in inhibiting cancer cell-specific gene transcription while also facilitating anti-cancer gene expression. 27058786 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.060 AlteredExpression group BEFREE HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. 17671421 2007
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 AlteredExpression group BEFREE HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. 17671421 2007
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.020 AlteredExpression phenotype BEFREE Increased HEXIM1 expression caused differentiation and inhibited proliferation and metastasis of cancer cells. 31805991 2019
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.020 AlteredExpression group BEFREE Known inhibitors of KDM5B were also able to induce HEXIM1 expression, inhibit cell proliferation, induce differentiation, potentiate sensitivity to cancer chemotherapy, and inhibit breast tumor metastasis. 31805991 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.020 AlteredExpression disease BEFREE Molecular target identification of HMBA and 4a1 could lead to further structural optimization of the parental compound to generate more potent derivatives to stimulate HEXIM1 expression, which could be a novel approach for hormone dependent breast cancer and prostate cancer treatment. 28213333 2017